CASTLE BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.53 USD | +5.85% |
|
+9.79% | -0.23% |
Chart calendar Castle Biosciences, Inc.
296b922293f767d004f43e704a833f6.PlvzOTrnclUcxja9WDazKwdXgHRhSKZTLi-csd3zwI4.dD-pW32lNDlZi2HfCGH8cU0U7wINIPMMTFzs67aq895uLbIBf4IrEU-jVQ~fc67c1506669a9b819afdc2017c18ceb
Upcoming events on Castle Biosciences, Inc.
Past events on Castle Biosciences, Inc.
| 09/04/2024 10:15 pm | Needham Healthcare Conference |
| 04/04/2024 | European Association of Dermato Oncology Congress - Abstract Number : A-128 |
| 04/04/2024 | European Association of Dermato Oncology Congress - Abstract Number : A-223 |
| 04/04/2024 | European Association of Dermato Oncology Congress - Abstract Number : A-262 |
| 19/03/2024 08:45 pm | KeyBanc Life Sciences & MedTech Forum |
| 17/03/2024 02:30 am | American Association for Geriatric Psychiatry Meeting |
| 10/03/2024 06:20 am | American Academy of Dermatology meeting - Abstract No : 51667 |
| 10/03/2024 12:00 am | American Academy of Dermatology meeting - Abstract No : 54153 |
| 08/03/2024 | American Academy of Dermatology meeting - Abstract No : 52819 |
| 29/02/2024 03:00 am | Q4 2023 Earnings Call |
| 29/02/2024 02:35 am | Q4 2023 Earnings Release |
| 28/11/2023 11:00 pm | Piper Sandler Healthcare Conference |
| 16/11/2023 07:30 pm | Canaccord Genuity MedTech Diagnostics and Digital Health and Services Forum |
| 15/11/2023 09:30 pm | Stephens Investment Conference |
| 03/11/2023 08:35 pm | American Academy of Ophthalmology Meeting - PTH02 |
| 03/11/2023 02:00 am | Q3 2023 Earnings Call |
| 03/11/2023 01:35 am | Q3 2023 Earnings Release |
| 25/10/2023 01:30 am | American College of Gastroenterology Scientific Meeting |
| 04/10/2023 05:45 am | American Society for Radiation Oncology Meeting - Abstract No - 1180 |
| 14/09/2023 | Lake Street Capital Markets Big7 Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 51,9 46,0 12.85% | 62,6 61,1 2.52% | 94,1 93,2 0.91% | 137 137 0.01% | 220 215 2.3% | 238 |
|
EBITDA Million USD | Released Forecast Spread | 7,69 3,49 119.93% | -6,07 -5,07 -19.7% | -36,7 -35,1 -4.46% | -62,3 -60,6 -2.9% | -55,6 -67,4 17.42% | -59,8 |
|
EBIT Million USD | Released Forecast Spread | 7,33 3,32 120.71% | -6,54 -5,60 -16.78% | -40,1 -37,4 -7.13% | -72,9 -72,6 -0.36% | -68,0 -76,3 10.92% | -69,4 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 5,35 1,55 245.88% | -10,2 -7,99 -27.73% | -40,0 -37,3 -7.2% | -68,9 -70,2 1.86% | -57,4 -68,7 16.46% | -61,2 |
|
Net income Million USD | Released Forecast Spread | 2,99 -5,55 153.88% | -10,3 -7,99 -28.79% | -31,3 -37,0 15.32% | -67,1 -71,5 6.07% | -57,5 -70,0 17.86% | -61,8 |
|
EPS USD | Released Forecast Spread | 0,35 -1,37 125.22% | -0,54 -0,41 -33% | -1,24 -1,46 15.26% | -2,58 -2,72 5.28% | -2,14 -2,60 17.83% | -2,24 |
| Announcement Date | 10/03/20 | 08/03/21 | 28/02/22 | 28/02/23 | 28/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 25,0 24,2 3.41% | 26,9 25,2 6.41% | 34,8 28,4 22.8% | 37,0 34,8 6.5% | 38,3 38,3 0% | 42,0 37,4 12.46% | 50,1 44,2 13.32% | 61,5 48,6 26.62% | 66,1 61,2 8.1% | 66,2 | 55,2 | 57,2 | 59,1 | 58,9 |
|
EBITDA Million USD | Released Forecast Spread | -13,7 -12,0 -14.38% | -11,4 -15,3 25.66% | -10,9 -9,83 -10.67% | -8,28 -10,2 18.86% | -20,0 -18,1 -10.74% | -15,1 -11,1 -36.27% | -5,27 -12,4 57.57% | 6,58 -14,2 146.35% | -2,43 -17,2 85.84% | -12,2 | -16,6 | -15,3 | -14,3 | |
|
EBIT Million USD | Released Forecast Spread | -15,2 -12,5 -20.91% | -22,0 -18,6 -17.77% | -22,7 -20,4 -10.87% | -21,7 -25,4 14.51% | -22,8 -22,6 -1.01% | -31,5 -25,5 -23.77% | -21,2 -26,1 19.06% | -9,64 -21,8 55.77% | -5,66 -15,5 63.53% | -11,1 | -20,5 | -19,2 | -18,5 | -20,6 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -15,2 -12,5 -21.02% | -24,5 -18,6 -31.42% | -3,61 -20,4 82.35% | -20,2 -25,2 19.75% | -20,6 -21,9 6.18% | -29,2 -24,2 -20.42% | -18,8 -24,4 23.18% | -6,87 -20,2 65.94% | -2,54 -13,8 81.64% | -8,94 | -18,5 | -17,3 | -16,5 | -19,0 |
|
Net income Million USD | Released Forecast Spread | -6,43 -12,1 47.03% | -24,6 -18,1 -36.11% | -1,65 -19,9 91.7% | -20,2 -23,2 12.61% | -20,6 -22,4 8.05% | -29,2 -23,7 -23.4% | -18,8 -24,6 23.58% | -6,91 -20,6 66.54% | -2,58 -15,2 83.01% | -9,08 | -18,8 | -17,5 | -16,4 | -19,1 |
|
EPS USD | Released Forecast Spread | -0,25 -0,48 47.37% | -0,97 -0,71 -37.17% | -0,06 -0,76 92.12% | -0,77 -0,88 12.5% | -0,78 -0,84 7% | -1,10 -0,89 -23.79% | -0,70 -0,92 23.5% | -0,26 -0,76 65.96% | -0,10 -0,56 82.21% | -0,33 | -0,68 | -0,63 | -0,59 | -0,67 |
| Announcement Date | 28/02/22 | 09/05/22 | 08/08/22 | 02/11/22 | 28/02/23 | 03/05/23 | 02/08/23 | 02/11/23 | 28/02/24 | - | - | - | - | - |
| Today 01:35 am | 10X GENOMICS, INC.: Q1 2024 Earnings Release |
| 02/05/2024 | MYRIAD GENETICS, INC.: Q1 2024 Earnings Release (Projected) |
| 02/05/2024 04:30 pm | LANTHEUS HOLDINGS, INC.: Q1 2024 Earnings Release |
| 03/05/2024 01:35 am | CASTLE BIOSCIENCES, INC.: Q1 2024 Earnings Release |
| 10/05/2024 | DIASORIN S.P.A.: Q1 2024 Earnings Release |
| 13/05/2024 | SD BIOSENSOR, INC: Q1 2024 Earnings Release (Projected) |
| 17/07/2024 11:30 am | VITROLIFE AB: Q2 2024 Earnings Release |
| 30/07/2024 | AMOY DIAGNOSTICS CO., LTD.: Q2 2024 Earnings Release (Projected) |
| 01/08/2024 | MYRIAD GENETICS, INC.: Q2 2024 Earnings Release (Projected) |
| 01/08/2024 | LANTHEUS HOLDINGS, INC.: Q2 2024 Earnings Release (Projected) |
Past sector events for Castle Biosciences, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- CSTL Stock
- Calendar Castle Biosciences, Inc.
